LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

Home・Stock List・Innoviva Inc

Innoviva Inc

Open

SectorHealthcare

22.83 1.69

Buy Sell

Overview

Share price change

24h

Current

Min

22.31

Max

22.91

Key metrics
By Trading Economics
Income	-55M 187M
Sales	-20M 98M
P/E Sector Avg	3.482 49.701
EPS	0.468
Profit margin	190.415
Employees	159
EBITDA	-160M 48M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+53.61% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-93M 1.6B
Previous open	21.14
Previous close	22.83

News Sentiment

By Acuity

50%

159 / 345 Healthcare

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 May 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 May 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 May 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 May 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 May 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 May 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 May 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 May 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 May 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 May 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 May 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 May 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 May 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 May 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 May 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 May 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 May 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 May 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 May 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 May 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 May 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 May 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

53.61% upside

12 Months Forecast

Average 34.5 USD 53.61%

High 46 USD

Low 18 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Sentiment

By Acuity

159 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.